Christopher Gibson Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Christopher Gibson is Chief Executive Officer of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 1.26 Million shares of RXRX, which is worth approximately $8.28 Million. The most recent transaction as insider was on Feb 18, 2025, when has been sold 17,132 shares (Class A Common Stock) at a price of $10.64 per share, resulting in proceeds of $182,284. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.26M

70.51% 3M change

13.68% 12M change

Total Value Held $8.28 Million

Christopher Gibson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 18 2025	SELL Payment of exercise price or tax liability	$182,284 $10.64 p/Share	17,132 Reduced 1.35%	1,256,024 Class A Common Stock
Feb 06 2025	SELL Open market or private sale	$162,399 $8.12 p/Share	20,000 Reduced 1.55%	1,273,156 Class A Common Stock
Feb 06 2025	BUY Conversion of derivative security	-	20,000 Added 1.52%	1,293,156 Class A Common Stock
Feb 05 2025	SELL Open market or private sale	$153,600 $7.68 p/Share	20,000 Reduced 1.55%	1,273,156 Class A Common Stock
Feb 05 2025	BUY Conversion of derivative security	-	20,000 Added 1.52%	1,293,156 Class A Common Stock
Feb 03 2025	SELL Payment of exercise price or tax liability	$40,375 $7.25 p/Share	5,569 Reduced 0.44%	1,273,156 Class A Common Stock
Feb 03 2025	BUY Grant, award, or other acquisition	-	542,092 Added 29.77%	1,278,725 Class A Common Stock
Jan 10 2025	SELL Open market or private sale	$141,000 $7.05 p/Share	20,000 Reduced 2.64%	736,633 Class A Common Stock
Jan 10 2025	BUY Conversion of derivative security	-	20,000 Added 2.58%	756,633 Class A Common Stock
Jan 08 2025	SELL Open market or private sale	$146,200 $7.31 p/Share	20,000 Reduced 2.64%	736,633 Class A Common Stock
Jan 08 2025	BUY Conversion of derivative security	-	20,000 Added 2.58%	756,633 Class A Common Stock
Dec 05 2024	SELL Open market or private sale	$142,400 $7.12 p/Share	20,000 Reduced 2.64%	736,633 Class A Common Stock
Dec 05 2024	BUY Conversion of derivative security	-	20,000 Added 2.58%	756,633 Class A Common Stock
Dec 04 2024	SELL Open market or private sale	$143,200 $7.16 p/Share	20,000 Reduced 2.64%	736,633 Class A Common Stock
Dec 04 2024	BUY Conversion of derivative security	-	20,000 Added 2.58%	756,633 Class A Common Stock
Nov 15 2024	SELL Payment of exercise price or tax liability	$160,561 $6.17 p/Share	26,023 Reduced 3.41%	736,633 Class A Common Stock
Nov 14 2024	SELL Open market or private sale	$147,000 $7.35 p/Share	20,000 Reduced 2.56%	762,656 Class A Common Stock
Nov 14 2024	BUY Conversion of derivative security	-	20,000 Added 2.49%	782,656 Class A Common Stock
Nov 13 2024	SELL Open market or private sale	$154,800 $7.74 p/Share	20,000 Reduced 2.56%	762,656 Class A Common Stock
Nov 13 2024	BUY Conversion of derivative security	-	20,000 Added 2.49%	782,656 Class A Common Stock
Oct 03 2024	SELL Open market or private sale	$121,600 $6.08 p/Share	20,000 Reduced 2.56%	762,656 Class A Common Stock
Oct 03 2024	BUY Conversion of derivative security	-	20,000 Added 2.49%	782,656 Class A Common Stock
Oct 02 2024	SELL Open market or private sale	$123,200 $6.16 p/Share	20,000 Reduced 2.56%	762,656 Class A Common Stock
Oct 02 2024	BUY Conversion of derivative security	-	20,000 Added 2.49%	782,656 Class A Common Stock
Sep 05 2024	SELL Open market or private sale	$122,800 $6.14 p/Share	20,000 Reduced 2.56%	762,656 Class A Common Stock

Christopher Gibson

Chief Executive Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account